Nilotinib Linked to Metabolic Syndromes and CVD in CML Nilotinib Linked to Metabolic Syndromes and CVD in CML
Investigators suggest using other TKIs in patients with preexisting diabetes and hyperlipidemia.Medscape Medical News (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - August 29, 2023 Category: Pathology Tags: Hematology-Oncology News Source Type: news
Nilotinib Linked to Metabolic Syndrome and CVD in CML Nilotinib Linked to Metabolic Syndrome and CVD in CML
Investigators suggest using other TKIs in patients with preexisting diabetes and hyperlipidemia.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - August 29, 2023 Category: Drugs & Pharmacology Tags: Hematology-Oncology News Source Type: news
Aurobindo Pharma arm signs pact with Medicines Patent Pool to develop anti-cancer drug
India's Aurobindo Pharma has announced that its subsidiary Eugia Pharma Specialities has signed a voluntary sub-licensing agreement with Medicines Patent Pool to develop and market an anti-cancer drug- Nilotinib capsules. Nilotinib capsules are used for the treatment of chronic myeloid leukemia. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 23, 2023 Category: Pharmaceuticals Source Type: news
Second-line nilotinib for Philadelphia chromosome-positive CML: more effective, less costly
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - August 1, 2021 Category: Drugs & Pharmacology Source Type: news
Myeloid Leukemia Drug Disappoints in Parkinson's Disease Myeloid Leukemia Drug Disappoints in Parkinson's Disease
Despite showing neuroprotective effects in preclinical models of Parkinson ' s disease, the tyrosine kinase inhibitor nilotinib does not appear to have a future for this condition.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - December 16, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
CML Drug Nilotinib Shows Early Effects in Alzheimer's Disease CML Drug Nilotinib Shows Early Effects in Alzheimer's Disease
Preliminary findings for the oral nonantibody drug show safety, significant changes in key Alzheimer ' s biomarkers.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 20, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Nilotinib Is Safe in Moderate and Advanced Parkinson's Disease Nilotinib Is Safe in Moderate and Advanced Parkinson's Disease
Although nilotinib is safe and tolerable in patients with moderate or advanced Parkinson ' s disease, it may not affect the disease ' s symptoms, according to investigators.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - May 29, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Leukemia drug nilotinib safe, shows promise against Alzheimer's disease
The leukemia drug nilotinib, which shows promise in reducing the effects of Alzheimer's disease, is safe and has minimal side effects when used at low doses, according to a small clinical trial published Friday. (Source: Health News - UPI.com)
Source: Health News - UPI.com - May 29, 2020 Category: Consumer Health News Source Type: news
Leukemia drug nilotinib safe, shows promise against Alzheimer's disease in trial
The leukemia drug nilotinib, which shows promise in reducing the effects of Alzheimer's disease, is safe and has minimal side effects when used at low doses, according to a small clinical trial published Friday. (Source: Health News - UPI.com)
Source: Health News - UPI.com - May 29, 2020 Category: Consumer Health News Source Type: news
Mixed Results With Leukemia Drug in Parkinson's Mixed Results With Leukemia Drug in Parkinson's
The authors say low doses of nilotinib were ' reasonably safe ' in this phase 2 trial, an assessment questioned by authors of an accompanying editorial.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - December 24, 2019 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Cancer drug shows promise in Parkinson's disease safety trial
A small clinical trial of nilotinib in people with Parkinson's disease finds that the cancer drug is reasonably safe and holds promise as a therapy. (Source: Parkinson's Disease News From Medical News Today)
Source: Parkinson's Disease News From Medical News Today - December 18, 2019 Category: Neurology Tags: Parkinson's Disease Source Type: news
Medical News Today: Cancer drug shows promise in Parkinson's disease safety trial
A small clinical trial of nilotinib in people with Parkinson's disease finds that the cancer drug is reasonably safe and holds promise as a therapy. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 18, 2019 Category: Consumer Health News Tags: Parkinson's Disease Source Type: news
SAE Rate Higher With Nilotinib Versus Placebo in Parkinson Disease
TUESDAY, Dec. 17, 2019 -- Among patients with moderately severe Parkinson disease, exploratory biomarkers are altered in response to nilotinib, but the rate of serious adverse events (SAEs) is significantly higher in those receiving nilotinib versus... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 17, 2019 Category: Pharmaceuticals Source Type: news
Cancer Drug Nilotinib Shows Promise for Parkinson's Patients
MONDAY, Dec. 16, 2019 -- A drug used to fight chronic myeloid leukemia might also relieve symptoms of Parkinson ' s disease, a new study finds.
In a phase 2 clinical trial, researchers found that the drug nilotinib (brand name: Tasigna) increased... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 16, 2019 Category: General Medicine Source Type: news
Cancer Drug Shows Promise for Parkinson's Patients
MONDAY, Dec. 16, 2019 -- A drug used to fight chronic myeloid leukemia might also relieve symptoms of Parkinson ' s disease, a new study finds.
In a phase 2 clinical trial, researchers found that the drug nilotinib (brand name: Tasigna) increased... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 16, 2019 Category: General Medicine Source Type: news
